<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381325</url>
  </required_header>
  <id_info>
    <org_study_id>MSB0254-CSP-001</org_study_id>
    <nct_id>NCT04381325</nct_id>
  </id_info>
  <brief_title>A Study of MSB0254 Injection in Advanced Solid Tumors</brief_title>
  <official_title>Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabspace Biosciences (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mabspace Biosciences (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was an open, multi-dose dose escalation phase I clinical study to evaluate the&#xD;
      safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or&#xD;
      metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MSB0254</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
    <description>Measured by number adverse events that are related to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose(MTD) or recommended phase2 dose（RP2D）</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
    <description>Measured by number of subjects experiencing DLT in each escalation cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for MSB0254</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>Changes in AUC over time in subjects with MSB0254</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma concentration (Cmax)for MSB0254</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>Cmax is the maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>Tmax is the time in hours/days to reach Cmax following dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>The time required for the plasma level of the study drug to decrease by one-half during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The immunogenicity of MSB0254 injection</measure>
    <time_frame>Up to 30 days following the last dose</time_frame>
    <description>The immunogenicity of MSB0254 injection was evaluated by testing the production of anti-drug antibody (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as measured by RESISTv1.1</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
    <description>Objective response rate (ORR) as measured by RESISTv1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as measured by RESISTv1.1</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
    <description>Duration of response (DOR) as measured by RESISTv1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as measured by RESISTv1.1</measure>
    <time_frame>Up to 90 days following the last dose</time_frame>
    <description>Progression-free survival (PFS) as measured by RESISTv1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>MSB0254 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This experiment will start from 4mg/kg with a dose increase of 3+3, and is planned to be carried out in 5 dose groups, namely 4mg/kg, 8mg/kg (100% increase), 12mg/kg (50% increase), 16mg/kg (33% increase) and 20mg/kg (25% increase).MSB0254 injection was administered intravenously on day 1 and day 15 every 28 days.To collect pharmacokinetic blood samples after repeated administration, MSB0254 injection was not administered on day 1 of the third cycle (C3D1).The observation period of DLT was 28 days after the first administration. An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSB0254 Injection</intervention_name>
    <description>An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).&#xD;
An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).</description>
    <arm_group_label>MSB0254 Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary informed consent, knowledge of the study and willingness to follow and has&#xD;
             ability to complete all trial procedures&#xD;
&#xD;
          -  There is a histologically or cytologically confirmed, locally advanced or metastatic&#xD;
             tumor by standard treatment failure or lack of standard treatment or inability to&#xD;
             tolerate standard treatment;&#xD;
&#xD;
        For patients enrolled in the extended period:&#xD;
&#xD;
        Group 1: vascular rich tumors, including but not limited to neuroendocrine tumors, thymic&#xD;
        squamous cell carcinoma and soft tissue Sarcoma, the specific categories are as follows. If&#xD;
        it is necessary to enroll other types of tumor subjects, it is necessary to cooperate with&#xD;
        the sponsor The responsible person shall discuss and confirm.&#xD;
&#xD;
          -  Neuroendocrine tumor (net): low and medium grade (G1 or G2) confirmed by&#xD;
             histopathology: low grade Other (G1) was defined as mitotic image number &lt; 2 / 10,&#xD;
             high power field of view [HPF] and / or Ki-67 differentiation Index &lt; 3%; The&#xD;
             intermediate level (G2) is defined as the number of mitotic images 2-20 / 10&#xD;
             high-power field of vision[HPF] and / or Ki-67 differentiation index 3-20%. If the&#xD;
             mitotic image and Ki of the same tumor tissue-67 indicators correspond to different&#xD;
             levels and follow higher levels;&#xD;
&#xD;
          -  Thymic squamous cell carcinoma (TSCC): thymic squamous cell carcinoma confirmed by&#xD;
             histology or cytology;&#xD;
&#xD;
          -  Soft tissue sarcoma (STS): soft tissue sarcoma confirmed by histology or cytology;&#xD;
&#xD;
        Group 2: hepatocellular carcinoma (HCC): hepatocellular carcinoma confirmed histologically&#xD;
        or cytologically. Barcelona Clinic Liver cancer stage B and C (BCLC B and C)&#xD;
&#xD;
          -  The eastern United States cooperative tumor group (ECOG) score was 0 or 1&#xD;
&#xD;
          -  Expect to survive at least 3 months&#xD;
&#xD;
          -  Must have at least one assessable lesion as defined in RECIST v1.1;&#xD;
&#xD;
          -  Suitable organs and hematopoietic function should be available. Laboratory tests&#xD;
             during screening should meet the appropriate criteria:&#xD;
&#xD;
          -  Male and female subjects of childbearing age will agree to use effective,&#xD;
             investigator-approved contraceptive methods from the date of the informed consent&#xD;
             until 3 months after the last administration&#xD;
&#xD;
          -  Previous treatment of subjects enrolled in the extended study:&#xD;
&#xD;
          -  Net: Net subjects with disease progression after at least 2-wire system antitumor drug&#xD;
             treatment regimen: connected Systematic treatment for unresectable net, followed by&#xD;
             recurrence / progression, or intolerance, or Unwilling to receive treatment. Frontline&#xD;
             treatment may include somatostatin analogues, interferon, PRRT (peptide) Receptor&#xD;
             radionuclide therapy), mTOR inhibitor or chemotherapy (unlimited chemotherapy drugs&#xD;
             and times, Chemotherapy is regarded as a drug treatment regimen), anti angiogenesis&#xD;
             drugs (including anti VEGF-A monoclonal antibody) Or VEGFR tyrosine kinase inhibitor);&#xD;
&#xD;
          -  Thymic squamous cell carcinoma and soft tissue sarcoma: failure of previous&#xD;
             conventional systemic chemotherapy;&#xD;
&#xD;
          -  HCC: HCC subjects with disease progression or intolerance after treatment with 2-line&#xD;
             system antitumor drugs: after receiving systematic treatment for unresectable HCC,&#xD;
             they relapse / progress, or are unable to tolerate Those who are affected or unwilling&#xD;
             to receive treatment. Frontline systemic therapy must include immune checkpoint&#xD;
             inhibitors and anti-inflammatory drugs Angiogenesis drugs (including anti-vegf-a&#xD;
             monoclonal antibody or VEGFR tyrosine kinase inhibitor).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had suffered from malignant tumors other than the primary tumor at the time of&#xD;
             enrollment within 5 years before screening (except: after Fully treated cervical&#xD;
             carcinoma in situ, local squamous cell carcinoma of the skin, basal cell carcinoma,&#xD;
             localized cancer Adenocarcinoma, ductal carcinoma in situ or stage I uterine cancer);&#xD;
&#xD;
          -  High grade (G3) neuroendocrine carcinoma, adenoid carcinoma, islet cell carcinoma,&#xD;
             goblet cell carcinoid, large Cellular neuroendocrine carcinoma and small cell&#xD;
             carcinoma;&#xD;
&#xD;
          -  Functional net and need to be accompanied by the use of long-acting somatostatin&#xD;
             analogues to control symptoms, such as insulinoma Gastrinoma, glucagon tumor,&#xD;
             somatostatin tumor, adrenocorticotropic hormone tumor, vascular activity Intestinal&#xD;
             peptidoma with carcinoid syndrome, zoai syndrome or disease-specific active symptoms-&#xD;
&#xD;
          -  Patients with symptoms of brain or pia meningeal metastases.&#xD;
&#xD;
          -  The lung metastasis of the tumor has a cavity, or the investigator judges that there&#xD;
             is bleeding tendency or bleeding risk;&#xD;
&#xD;
          -  patients requiring local treatment or repeated drainage, the investigator identified&#xD;
             poorly controlled effusion of the body cavity (pleural fluid, ascites, pericardial&#xD;
             effusion, etc.)&#xD;
&#xD;
          -  The adverse reactions of previous treatment did not recover to CTCAEv5.0 score ≤1&#xD;
             (excluding hair loss and anemia);&#xD;
&#xD;
          -  Had received any previous systemic therapy targeting VEGF or VEGFR2 signaling pathway;&#xD;
&#xD;
          -  Drugs or chemotherapy or radiotherapy received in other clinical trials within 4 weeks&#xD;
             prior to enrollment (mitomycin C and nitrosorea should be administered at least 6&#xD;
             weeks before the last dose)&#xD;
&#xD;
          -  Patients who had major surgery within 4 weeks prior to screening (excluding needle&#xD;
             biopsy) and who were expected to have major surgery during the study period (including&#xD;
             the 28-day screening period) or had severe unhealed wounds, ulcers, or trauma&#xD;
&#xD;
          -  Left ventricular ejection fraction ≤50%;&#xD;
&#xD;
          -  Heart failure patients with greater than or equal to Ⅱ level（NYHA）;&#xD;
&#xD;
          -  Clinically significant arrhythmias (including frequent ventricular premature beats,&#xD;
             symptomatic or treatable ventricular tachycardia, and asymptomatic persistent&#xD;
             ventricular tachycardia);&#xD;
&#xD;
          -  After regular antihypertensive treatment for 4 weeks, the blood pressure did not reach&#xD;
             systolic blood pressure &lt; 150mmhg and / or diastolic blood pressure &lt; 150mmhg 90mmHg,&#xD;
             or after regular antihypertensive treatment, the blood pressure reaches systolic blood&#xD;
             pressure &lt; 150mmhg and / or diastolic blood pressure The duration of pressure &lt; 90mmHg&#xD;
             is less than 4 weeks&#xD;
&#xD;
          -  There are currently venous thromboemboli that require treatment;&#xD;
&#xD;
          -  Myocardial infarction, stroke or other severe arterial thromboembolism events occurred&#xD;
             within 6 months before enrollment.&#xD;
&#xD;
          -  Any grade 2 or more bleeding occurred within 6 months prior to enrollment;&#xD;
&#xD;
          -  Intraperitoneal abscess, or abdominal wall fistula, gastrointestinal perforation, or a&#xD;
             history of poorly controlled/recurrent inflammatory bowel disease (including crohn's&#xD;
             disease or ulcerative colitis) occurred within 6 months prior to enrollment.&#xD;
&#xD;
          -  The patient is receiving （NSAIDS;Such as indomethacin, ibuprofen, naproxen or similar&#xD;
             drugs) or antiplatelet drugs (such as clopidogrel, ticlopidine, dipyridamole or&#xD;
             analgrel) for long-term treatment;Aspirin is permitted with a maximum dose of 325 mg&#xD;
             per day;Celecoxib is permitted for analgesic treatment;However, low-dose aspirin&#xD;
             (≤325mg/d) and celecoxib should not be used at the same time.&#xD;
&#xD;
          -  Patients are known to be allergic to MSB0254 or its excients, monoclonal antibodies,&#xD;
             or any other therapeutic protein, such as fresh frozen plasma, human serum albumin&#xD;
             (HSA), cytokines, or interleukin.If severe allergic reactions are suspected (CTCAE&#xD;
             v5.0 grade ≥3), the patient should be excluded.&#xD;
&#xD;
          -  Urine protein concentration of patients according to dipstick or routine urine&#xD;
             analysis (UA) is &gt;1 +,The patients also had edema or serum albumin levels below the&#xD;
             lower limit of the normal range (LLN).Alternatively, if the urine protein&#xD;
             concentration of the patient is ≥2+ according to the dipstick or routine urine&#xD;
             analysis, the urine protein concentration in the 24-hour urine protein analysis must&#xD;
             be&gt;1g, accompanied by edema or serum albumin lower than LLN;&#xD;
&#xD;
          -  Patients with a known history of hepatitis c or chronic active hepatitis b. Except for&#xD;
             HBV carriers, hepatitis b patients who are stable after drug treatment (hbv-dna titer&#xD;
             must not be higher than 1000 copies [CPS]/mL or 200 IU/mL) and hepatitis c patients&#xD;
             who are stable after drug treatment (hcv-rna negative)&#xD;
&#xD;
          -  A known history of HIV infection or a positive test for human immunodeficiency virus&#xD;
             (HIV);&#xD;
&#xD;
          -  Positive treponema pallidum test;&#xD;
&#xD;
          -  A history of alcohol, drug or substance abuse in the past 1 year;&#xD;
&#xD;
          -  Has a clear history of neurological or mental disorders, such as epilepsy or dementia;&#xD;
&#xD;
          -  Poor compliance of the subject;&#xD;
&#xD;
          -  Women who are pregnant (confirmed by a urine or serum pregnancy test) or&#xD;
             breast-feeding;&#xD;
&#xD;
          -  the investigators concluded that the study was not suitable for participants for other&#xD;
             reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mengde Wang</last_name>
    <role>Study Director</role>
    <affiliation>Mabspace Biosciences (Suzhou) Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Yue</last_name>
    <phone>+86-512-67079200</phone>
    <phone_ext>8009</phone_ext>
    <email>ming.yue@transcenta.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling Sun</last_name>
    <phone>+86-512-67079200</phone>
    <phone_ext>8009</phone_ext>
    <email>ling.sun@transcenta.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yulong Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FuDan University ZhongShan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TianShu Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

